A guide for potency assay development of cell-based product candidates

The development of a potency assay for cellular therapy products entails many steps of innovations and discoveries, while keeping in mind the end user and the requirements of the regulatory authorities.

October7th,2013
Dr. Malki Epel, Pluristem
A relevant and robust potency assay is not only a regulatoryrequirement, but it is also the basis for producing and delivering a productthat works, and is therefore one of the most important and challenging issueswhen developing and testing cell-based therapies.
 
The potency assay plays a key role in determining thequality of biological products including cellular therapy products (CTPs). Asdefined in the U.S. Code of Federal Regulations (21 CFR 600.3), the potency isthe specific ability or capacity of the product to effect a given result. Thepotency assay is a quantitative test that confirms the therapeutic productprovides a particular response at a certain dose. Since a mechanism of action(MoA) refers to the specific interaction through which the CTP produces itspharmacological effect, it is ideal that the potency assay will represent theproduct's known or intended MoA.
 
Throughout the drug discovery and development process, newdata is accumulated on the product candidate's MoA. Thus, a potency assay usedin early stages of product development may be deemed non-optimal in laterstages of the development, as a deeper understanding of the MoA for a specifictherapy is gained. For example, in a proposed anti-inflammatory potency assayfor a specific product candidate with what is initially believed to be ananti-inflammatory, MoA may require an alternative, non-anti-inflammatorypotency assay as additional data is accumulated from in-vitro and in-vivostudies, suggesting a new MoA product candidate. As a result, an initialpotency assay may be replaced. It is also important to note that during earlyproduct development stages, a potency assay may be developed to target the mostcritical biological activity of the product candidate known at this time, whilein later stages, additional relevant potency assays may be added.
 
Stages in potencyassay development
 
The development of a potency assay for cellular therapyproducts entails many steps of innovations and discoveries, while keeping inmind the end user and the requirements of the regulatory authorities.
 
The first step in developing a potency assay for a specificcellular therapy product is to understand the biological basis of thedisease(s) that the product aims to treat, as well as having a good grasp of theproduct's MoA. For example, if a cellular therapy product is hypothesized toelicit a pro-angiogenic response which may be mediated through pro-angiogeniccytokines, the specific pro-angiogenic pathways and relevant factors should beidentified and based on those scientific results, a potential potency assaycould be developed.
 
The second step in the assay development should be theconvenience of the assay to the end user. Since potency assays are performed asroutine quality control (QC) tests, the analysis and quantification of thedeveloped assay should be as simple as possible for the person performing theanalysis. In-vivo tests as a potencyassay should be avoided, as these are too complicated, time-consuming andexpensive. It is also recommended for cellular therapy product not to usesingle protein detection for a potency assay, as cells are likely to mediatetheir therapeutic function via multifactorial MoAs. Therefore, potency assayshould on one hand reflect the in-vivoprocess, and on the other hand, should be able to easily and routinelyperformed by QC personnel.
 
In the early stages of product development, the potencyassay results may not have defined acceptance criteria, and may be collectedand documented for information purposes only. However, during clinicaldevelopment, as part of the final stage in potency assay development, regulatoryauthorities expect manufacturers to define the potency assay acceptancecriteria, particularly prior to the initiation of pivotal Phase III clinical trials.The acceptance criteria for the assay should be based on accumulated datacollected from assays performed during all phases of product development andclinical trials, and should be based on a correlation with efficacy asdetermined in an in-vivo test.
 
To obtain a biologics license, a validated potency assaywith defined acceptance criteria must be described and justified in the biologicslicense application. Only a validated assay with defined acceptancecriteria can be used, which assures manufacturing consistency. Without suchparameters, there is no certainty that patients receiving the product candidatewill get a consistent potent cellular therapy product.
 
Potency assay as atool
 
In addition to measuring a cellular therapy product's activity,a potency assay is also used as a tool to test the comparability between lots,which were manufactured either following upgrades or as a result of changes tothe manufacturing process. Manufacturing process changes may include changes inharvesting procedure, in final product filling or when establishing a newmanufacturing line in a new facility. Such upgrades or changes may occur duringproduct development and clinical trials. Therefore, the potency assay has animportant role in comparing the products manufactured before and after anyupgrades or changes.
 
A potency assay is also a central tool to test productstability, and therefore should be included in all stability programs. Althoughviability/recovery of the cells may indicate the stability of the product,viable cells may lose their biological activity during storage.  Only cells shown to be potent post-storagecan be used.
 
Potency assayconsiderations
 
When developing potency assays, companies have to considerand address several fundamental issues:
    CTP's MoA is usually multifactorial; was an appropriate assay chosen?Is the assay robust and stable?
    For in-vitro cell-based assays, does the heterogeneity of the cells used in the assay undermine the stability of the assay?
    What are the proper positive and negative controls?
    What is the proper reference sample?
A cell-based potency assay may have several factors thatcause assay variability. Therefore, the sources for assay variability should beconsidered and limited as much as possible. To this end, critical reagentsshould be qualified and calibrated, only qualified equipment should be used andonly trained analysts should perform the assay. Elaborated standard operating procedures should be written and be used and controls should be included in theassay.
 
Since the potency assay is critical in assuring the qualityand consistency of the product, but must eliminate inherent variability in thetest system, a relative potency and not absolute potency should be specified.The relative potency is calculated by comparing the biological activity of thetested sample to a reference standard. The reference standard should beprepared by using the same manufacturing process as the cell-based product.
 
Several factors should be taken into account whileconducting an in-vitro cell-basedassay: the cells used in the assay should be characterized and banked beforebeing used for routine testing by QC. System suitability consists of prespecifiedcriteria by which the validity of the assay is assessed, and should beintegrated in each run of the assay to ensure the quality of the assay results.Outliers, that may be random events, should be predefined and omitted beforerelative potency analysis.
 
Most cell-based assays are performed using a cell culture plate.Complete randomization or at least plate layout of samples is the best approachto minimize plate effects.
Although regulatory authorities do not require a fullyvalidated potency assay until the end of pivotal Phase III clinical trials, itis important that the development of an assay be initiated early during thedevelopment program to have enough time for the validation parameters. It isexpected that accuracy, sensitivity, specificity, precision (repeatability,intermediate precision), linearity and range, system suitability and robustnesswill be established in order to achieve validated potency assay in the future.
 
Dr. Malki Epel has managed the quality control team atPluristem Therapeutics, a cell therapy company in Haifa, Israel, since 2009.Epel earned her Ph.D. in biology from the Technion Institute in Israel, whereshe specialized in the areas of  T cell receptor-like antibodies.
 
 
 
 

 
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all the latest DDN news!

Latest Issue's Magazine Cover

Latest Issue  

• Volume 16 • Issue 10 • November 2020

November 2020

November 2020 Issue